Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07449702 · ClinicalTrials.gov registry record · Phase 2
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
A Phase 2 study of Plaque Psoriasis, sponsored by Oruka Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 6
- Study locations
NCT07449702 is a Phase 2 study of Plaque Psoriasis that is actively recruiting participants, run by Oruka Therapeutics. The registered enrollment target is 80 participants, below the 414-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (81% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT07449702, a Phase 2 study of Plaque Psoriasis, is actively recruiting participants, sponsored by Oruka Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 6
- Study locations
Study Summary
An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.
Conditions Studied
Interventions
- DRUG ORKA-001
Study Locations (6)
California
- Oruka Therapeutics Investigative Site - Los Angeles
- Oruka Therapeutics Investigative Site - San Diego
Florida
- Oruka Therapeutics Investigative Site - Coral Gables
Kentucky
- Oruka Therapeutics Investigative Site - Bowling Green
Maryland
- Oruka Therapeutics Investigative Site - Rockville
Ontario
- Oruka Therapeutics Investigative Site - Peterborough
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-02-23 |
| Est. Completion | 2029-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07449702
The ClinicalTrials.gov registry entry for NCT07449702 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 414-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (81% lower). The listed sponsor is Oruka Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which ORKA-001 is the first listed.
NCT07449702 reports 6 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Kentucky.
Frequently Asked Questions
What is clinical trial NCT07449702 about?
NCT07449702 is a clinical study titled "An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis". An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.
What is the current status of trial NCT07449702?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2026-02-23. Estimated completion is 2029-01.
What conditions does trial NCT07449702 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT07449702?
The interventions under investigation include: ORKA-001 (DRUG).
Who is sponsoring clinical trial NCT07449702?
This trial is sponsored by Oruka Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07449702 being conducted?
This trial has 6 study locations across California, Florida, Kentucky, Maryland, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
RECRUITING · Phase 2
-
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 2
-
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 2
-
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression
COMPLETED · Phase 2
-
Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.